SAGE - Sage Therapeutics

-

$undefined

N/A

(N/A)

Sage Therapeutics NasdaqGM:SAGE Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Location: 55 Cambridge Parkway, Cambridge, MA, 02142, United States | Website: https://www.sagerx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

159.7M

Cash

423.9M

Avg Qtr Burn

-77.77M

Short % of Float

10.17%

Insider Ownership

10.41%

Institutional Own.

83.72%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zulresso (brexanolone) Details
PPD (Postpartum depression)

Approved

Quarterly sales

Approved

Quarterly sales

SAGE-319 Details
Cognitive Dysfunction

Phase 1

Data readout

SAGE-718 Details
Cognitive Dysfunction, Parkinson's disease

Failed

Discontinued

Dalzanemdor (SAGE-718) Details
Huntington's disease, Cognitive Dysfunction

Failed

Discontinued

Failed

Discontinued

Dalzanemdor ( SAGE-718 ) Details
Cognitive Dysfunction, Alzheimer's disease

Failed

Discontinued

Dalzanemdor (SAGE-718) Details
Huntington's disease, Cognitive Dysfunction

Failed

Discontinued